Proof that Patterson is unblinded: the IVRS number
OK,
Proof that Patterson is unblinded: the IVRS number
OK, so blafarm's post includes several pastes from investorshub.
One of those pasted posts identifies something called an "IVRS" number.
The investorshub poster further claims that every clinical trial sample includes a unique patient identifier, known as the "IVRS" number.
IVRS stands for Interactive Voice Response System. Apparently the unique patient identifier got its start as a code word which grants medical care practitioners acces to a particular human clinical trial and or supply system through an automated attendant.
So it looks like the FDA does have a protocol, and that protocol does include unique patient identifier on every blood sample vial.
Which means that Patterson can easily tracky patients through the study.
And when the primary endpoint is mortality, Patterson easily computes the trial primary endpoint, including p-value, as he recognizes that if the samples stop coming in then probably the patient died.
Patterson has sufficient experience that he can compute the severe/critical mortality primary endpoint in his head.
Heck, he probably re-computes the primary trial endpoint p-value every evening just for fun.
Now the only remaining question is whether he is allowed to tell anyone about this.
It is notable that Patterson is the ONLY person who can compute the primary endpoint in realy time because 1) Patterson is the ONLY person who has acces to all patients, and 2) Patterson MAY BE the only person who has access to the CCR5 receptor occupancy assay needed to discriminate between leronlimab and placebo.
5
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...
Continue Reading
Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...
Continue Reading
A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...
Continue Reading
A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...
Continue Reading
When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...
Continue Reading
Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...
Continue Reading
High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...
Continue Reading
Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...
Continue Reading
Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...
Continue Reading
Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...
Continue Reading
Top 5 Most Recently Viewed Articles
Highlights from Omni-Lite's Third Quarter Fiscal 2025 Outstanding Financial Performance Omni-Lite Industries Canada Inc. (TSXV: OML) recently reported its financial results for the third quarter of fiscal 2025, demonstrating notable growth and resilience. With revenue reaching approximately US$4.0 million, Omni-Lite saw a remarkable year-over-year increase of 7.0%...
Continue Reading
Understanding the Current UK Housing Market Dynamics The U.K. housing market is currently facing a notable slowdown, primarily driven by tax-related uncertainties associated with fiscal policies. As potential buyers adopt a more cautious stance, residential property transactions have seen a decline. This trend poses immediate risks for sectors linked to housing, including...
Continue Reading
Exciting New Driving Experiences at Radford Racing School Recently, Radford Racing School, known as a leader in performance driving education, announced its latest offerings that promise to thrill automotive enthusiasts of all ages and skill levels. With the introduction of six new driving experiences, there's now something for everyone at their legendary racetrack....
Continue Reading
AppLovin CEO's Notable Stock Sale Recently, AppLovin Corp (NASDAQ: APP) made headlines with a significant financial event: CEO and Chairperson Arash Adam Foroughi sold over $21.5 million worth of company stock. According to the latest SEC filing, this noteworthy transaction occurred over just two days, with share prices varying from $98.08 to $112.33 during that time....
Continue Reading
Olverembatinib Gains Breakthrough Therapy Designation Ascentage Pharma, a prominent global biopharmaceutical company, is making significant strides in the treatment of serious medical conditions. With its latest achievement, olverembatinib has secured a Breakthrough Therapy Designation in China for its use alongside low-intensity chemotherapy in newly-diagnosed patients...
Continue Reading